Primary ependymoma of the ovary, in which long-term oral etoposide (VP-16) was effective in prolonging disease-free survival.
BACKGROUND
Ovarian ependymoma is an extremely unusual teratoma of the ovary with only eight cases previously reported in the literature worldwide.


METHODS
A 26-year-old woman presented in 1992 with a sensation of abdominal fullness. The laparotomy revealed ovarian cancer (stage III), which proved to be an ependymoma pathologically. Three courses of the PVP regimen (cisplatin, vinblastine, peplomycin) and pelvic irradiation were administered postoperatively. Oral administration of etoposide (VP-16) was initiated after the residual tumor began to proliferate, and the tumor decreased in size and never regrew during etoposide administration for a total of 5 years and 8 months. The recurrent tumor was observed soon after the drug was discontinued.


CONCLUSIONS
Oral administration of etoposide was effective in prolonging disease-free survival.
Mikami
M
M
Department of Obstetrics and Gynecology, National Saitama Hospital, Suwa 2-1, Wako, Saitama 351-0102, Japan. mmikami@jun.ncvc.go.jp
Komuro
Y
Y
Sakaiya
N
N
Tei
C
C
Kurahashi
T
T
Komiyama
S
S
Hirose
T
T
D000284:Administration, Oral; D000328:Adult; D000972:Antineoplastic Agents, Phytogenic / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D004806:Ependymoma / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery; D005047:Etoposide / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy / Q000601:surgery
D000972:Antineoplastic Agents, Phytogenic; D005047:Etoposide